A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- San Francisco and West Los Angeles, United StatesSee the 2 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 26 people enrolled
- Started
- 13 Jan 2020
- Ended
- 31 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Oxytocin
- Placebo
- Record updated
- 20 January 2026
- Why it stopped
- Inadequate Subject Recruitment
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Veteran
- age 18-70
- a diagnosis of schizophrenia, schizophreniform, schizoaffective, or brief psychotic disorder determined by the Structured Clinical Interview for DSM-5
- no medication changes or psychiatric hospitalizations in the past month
- SFS modified raw score of no more than 75
Who cannot take part
- currently taking high dose testosterone or estrogen/progesterone
- substance use disorder in the past month, except mild to moderate cannabis use disorder
- illness affecting the nasal passages
- significant neurological/medical disorder
- pacemakers
- extensive dental work
- claustrophobia
- deafness
- inability to read
- currently participating in a psychosocial intervention targeting social functioning deficits
- inability to complete VOT
Where in United States
- San Francisco VA Medical Center, San Francisco, CASan Francisco, United States
- VA Greater Los Angeles Healthcare System, West Los Angeles, CAWest Los Angeles, United States
About the trial
What the trial wants to find out
Schizophrenia has a devastating and disproportionate effect on veterans compared to the general US population. Some of the most disabling symptoms, such as low motivation, difficulty expressing emotions, and decreased ability to infer the mental states of others, cause poor social functioning. This means that veterans with schizophrenia have trouble navigating interpersonal interactions and building meaningful relationships in the community. Unfortunately, current antipsychotic medications typically only improve positive symptoms but fail to improve social functioning deficits, which are strong predictors of poor quality of life and functional outcomes. Oxytocin, a peptide found in the brain, plays an important role in social behavior and is known to moderate affiliation, stress, and learning across taxa. In this study, the investigators will test whether oxytocin could be an effective treatment for social functioning deficits in schizophrenia. The investigators will examine changes in brain activation to understand how oxytocin affects behavior and to predict which individuals may benefit from oxytocin treatment.
The 2 groups in the trial
- Intranasal OxytocinTreatment being tested
Dosages of oxytocin: 20IU or 40IU.
Treatment: Oxytocin
- PlaceboPlacebo, for comparison
Saline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 20 January 2026